BR112023000065A2 - Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmos - Google Patents
Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmosInfo
- Publication number
- BR112023000065A2 BR112023000065A2 BR112023000065A BR112023000065A BR112023000065A2 BR 112023000065 A2 BR112023000065 A2 BR 112023000065A2 BR 112023000065 A BR112023000065 A BR 112023000065A BR 112023000065 A BR112023000065 A BR 112023000065A BR 112023000065 A2 BR112023000065 A2 BR 112023000065A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- methods
- crystalline form
- preparation
- pyrimidine compound
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- -1 PYRIMIDINE COMPOUND Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010737039 | 2020-07-28 | ||
| PCT/CN2021/108032 WO2022022398A1 (zh) | 2020-07-28 | 2021-07-23 | 一种嘧啶类化合物的盐和晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023000065A2 true BR112023000065A2 (pt) | 2023-01-31 |
Family
ID=80037147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000065A BR112023000065A2 (pt) | 2020-07-28 | 2021-07-23 | Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230295174A1 (https=) |
| EP (1) | EP4190781A4 (https=) |
| JP (1) | JP7688690B2 (https=) |
| KR (1) | KR20230044358A (https=) |
| CN (1) | CN115702154A (https=) |
| BR (1) | BR112023000065A2 (https=) |
| WO (1) | WO2022022398A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120897743A (zh) * | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| US20080234267A1 (en) * | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| BR112018000808A2 (pt) * | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| WO2018136661A1 (en) * | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2020114388A1 (zh) * | 2018-12-06 | 2020-06-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途 |
| CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
| JP7615056B2 (ja) * | 2019-02-19 | 2025-01-16 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 複素環化合物、これを含む薬物組成物、その製造方法および使用 |
| KR20230159367A (ko) | 2021-03-24 | 2023-11-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 키나아제 약물 내성 돌연변이와 관련된 질병의 치료에있어서의 헤테로사이클릭 화합물의 용도 및 그 방법 |
-
2021
- 2021-07-23 WO PCT/CN2021/108032 patent/WO2022022398A1/zh not_active Ceased
- 2021-07-23 KR KR1020227041673A patent/KR20230044358A/ko active Pending
- 2021-07-23 EP EP21849031.6A patent/EP4190781A4/en active Pending
- 2021-07-23 CN CN202180038857.0A patent/CN115702154A/zh active Pending
- 2021-07-23 US US18/017,104 patent/US20230295174A1/en active Pending
- 2021-07-23 BR BR112023000065A patent/BR112023000065A2/pt unknown
- 2021-07-23 JP JP2023503101A patent/JP7688690B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535361A (ja) | 2023-08-17 |
| KR20230044358A (ko) | 2023-04-04 |
| JP7688690B2 (ja) | 2025-06-04 |
| CN115702154A (zh) | 2023-02-14 |
| EP4190781A4 (en) | 2023-12-27 |
| WO2022022398A1 (zh) | 2022-02-03 |
| US20230295174A1 (en) | 2023-09-21 |
| EP4190781A1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004951A (es) | Proceso para la preparacion de pirazolo[1,5-a]pirimidinas y sales de estas. | |
| MX2020012765A (es) | Métodos y compuestos de ácido nucleico modificado con lípidos. | |
| JOP20220305A1 (ar) | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري | |
| BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
| BR112023000065A2 (pt) | Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmos | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| EA201500875A1 (ru) | СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
| BR112015031864A2 (pt) | compostos de pirimidinadiona contra as condições cardíacas | |
| EP4248988A3 (en) | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| MY201832A (en) | Sulfonamide compounds and use thereof | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| AR110768A1 (es) | Formas cristalinas de tenofovir alafenamida | |
| EA201991921A1 (ru) | Способы получения ag-10, его промежуточных соединений и их солей | |
| AU2019333310A8 (en) | Salts and crystal forms of GABAA positive allosteric modulator | |
| CL2019001804A1 (es) | Activador de nrf2. | |
| CO2020012574A2 (es) | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida | |
| EA201992360A1 (ru) | Кристаллические формы (s)-афоксоланера | |
| BR112014001299A2 (pt) | forma cristalina do sal de sódio de 4-terc-butil-n-[4-cloro-2-(1-óxi-piridina-4-carbonil)-fenil]-benzenossulfonamida | |
| EA201891431A1 (ru) | Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина | |
| CL2018002344A1 (es) | Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina | |
| HUE055530T2 (hu) | 7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| MX2025001201A (es) | Sales y cristales novedosos | |
| UY37477A (es) | Potenciadores de bmp |